Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Third Time's The Charm? Oritavancin Finds New Home With Targanta

This article was originally published in The Pink Sheet Daily

Executive Summary

Indianapolis-based private biotech firm will take over development of the Lilly-developed Phase III antibiotic, which was previously held by InterMune.

You may also be interested in...



Targanta Files Oritavancin NDA For cSSSI, Aiming To Tackle Vancomycin Market

Third owner of Lilly-developed compound touts antibiotic’s shorter course of treatment and dosing advantages over competing therapies.

Targanta Files Oritavancin NDA For cSSSI, Aiming To Tackle Vancomycin Market

Third owner of Lilly-developed compound touts antibiotic’s shorter course of treatment and dosing advantages over competing therapies.

InterMune Phase III Efforts Will Be Funded Through Infergen Sale

Proceeds from InterMune’s sale of the hepatitis C agent to Valeant will be used for development of idiopathic pulmonary fibrosis therapies.

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel